Salt Lake City-based Known Medicine on Wednesday said it has closed a $7.2 million seed funding round, which it will use to advance its 3D organoid modeling technology, Precision Oncology News reports.
The seed funding round was led by Caffeinated Capital. Other investors contributing funds included Khosla Ventures, Cota Capital, Kickstart, Forward VC, and OATV, as well as angel investors Chris Gibson, Recursion Pharmaceuticals’ CEO and cofounder, and Nish Bhat, co-founder and former chief technology officer of Color, among others.
Known Medicine predicts how well a patient’s tumor will respond to a particular therapy using its Oncology Diagnostics Inference Network platform. Read more.
